Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 12Myeloproliferative Disorders 2Leukemia, Biphenotypic, Acute 2Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Patient Preference 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Leukemia, Myeloid, Chronic-Phase 1GATA2 Deficiency 1Colorectal Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 44fludarabine phosphate 39Peripheral Blood Stem Cell Transplantation 36Busulfan 33Antilymphocyte Serum 26Cyclosporine 25Tacrolimus 24Filgrastim 23Mycophenolic Acid 22Methotrexate 22Radiotherapy 21Melphalan 16Etoposide 15Cytarabine 15Whole-Body Irradiation 14Methylprednisolone 13Cord Blood Stem Cell Transplantation 12Biopsy 8Azacitidine 8Sirolimus 7Flow Cytometry 7Cyclosporins 7Alemtuzumab 7Thiotepa 6Specimen Handling 6Psychiatric Rehabilitation 6Decitabine 6sargramostim 5ruxolitinib 5Rituximab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × decitabine and cedazuridine drug combination × Other hematologic neoplasm × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡